Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical firm Kamada has received orphan drug designation for its aerosolized Alpha-1 Antitrypsin product to treat bronchiectasis.
Subscribe to our email newsletter
Kamada’s aerosolized Alpha-1 Antitrypsin product is currently undergoing Phase II clinical trials.
David Tsur, CEO of Kamada, said: “This significant recognition grants Kamada various benefits such as research fund support, tax incentives, reduced user fees and seven years of exclusive distribution rights, if the company’s product is first on the US market for this indication.”